Cite

    Piñana, J. et al. (2017). A risk‐adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. Transplant infectious disease. 19 (4), p. n/a. [Online].